Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

Bradykinin, an endogenous vasodilator peptide, is metabolized by ACE. The aims of the present study were to determine the doses of B9340, a bradykinin receptor antagonist, that inhibit vasodilatation to exogenous bradykinin and to assess the contribution of bradykinin to the maintenance of basal vas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2001-10, Vol.104 (18), p.2177-2181
Hauptverfasser:	WITHEROW, Fraser N, HELMY, Ahmed, WEBB, David J, FOX, Keith A. A, NEWBY, David E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - administration & dosage Adult Aged Angiotensin-Converting Enzyme Inhibitors - administration & dosage Biological and medical sciences Blood Flow Velocity - drug effects Blood Pressure - drug effects Bradykinin - administration & dosage Bradykinin - analogs & derivatives Bradykinin - antagonists & inhibitors Bradykinin Receptor Antagonists Cardiovascular system Dose-Response Relationship, Drug Double-Blind Method Drug Synergism Female Forearm - blood supply Heart Failure - drug therapy Heart Failure - physiopathology Heart Rate - drug effects Humans Infusions, Intravenous Male Medical sciences Middle Aged Miscellaneous Pharmacology. Drug treatments Plethysmography Reference Values Regional Blood Flow - drug effects Substance P - administration & dosage Vasodilation - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!